Broad-spectrum Antivirals
Broad-spectrum Antivirals - Related Videos
11:34
High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
0 Views •
Cited by 14 •
2014
In vitro assays to measure virus replication have been greatly improved by the development of recombinant RNA viruses expressing luciferase or other enzymes capable of bioluminescence. Here we detail a high-throughput screening pipeline that combines such recombinant strains of measles and chikungunya viruses to isolate broad-spectrum antivirals from chemical libraries.
12:02
Assays for the Identification of Novel Antivirals against Bluetongue Virus
0 Views •
Cited by 11 •
2013
Three assays, including the cytopathic effect (CPE)-based assay, dose-response assay and Time-of-Addition (ToA) assay have been developed, optimized, validated and utilized to identify novel antivirals against Bluetongue virus (BTV), as well as to determine the possible Mechanism-of-Action (MoA) for newly identified antivirals.
02:37
The Electromagnetic Spectrum
0 Views •
2020
The electromagnetic spectrum consists of all the types of electromagnetic radiation arranged according to their frequency and wavelength. Each of the various colors of visible light has specific frequencies and wavelengths associated with them, and you can see that visible light makes up only a small portion of the electromagnetic spectrum. Because the technologies developed to work in various parts of the electromagnetic spectrum are different, for reasons of convenience and historical...
02:57
Assessing Antiviral Cytokine Production in Response to Viral Infection
0 Views •
2026
Source: Zhang, J., et al. Dissecting Innate Immune Signaling in Viral Evasion of Cytokine Production. J. Vis. Exp. (2014)This video demonstrates the process of infecting murine fibroblast cells with herpesvirus and monitoring the resulting antiviral cytokine release and gene expression. It outlines key steps, including viral infection, media collection for cytokine quantification, and cell harvesting for gene expression analysis.
02:48
Determining Antiviral Efficacy of Experimental Drugs Through a Plaque Assay
0 Views •
2025
This video demonstrates the method to perform a plaque assay using a virus obtained from infected porcine cornea. The porcine cornea is used to test the antiviral efficacy of experimental drugs.
FAQs
The value of targeting conserved viral steps lies in their recurrence across otherwise different pathogens. Inhibiting entry, genome replication, or protease-mediated protein processing can interrupt infection at points shared by multiple viruses. This strategy may preserve activity when the specific causative virus has not yet been identified.
Direct approaches act on viral functions such as genome replication or protein processing, whereas host-directed drugs interfere with cellular pathways that viruses depend on. Other agents enhance innate antiviral defenses rather than blocking one viral component. These mechanisms broaden potential coverage, but each requires evaluation across viruses and patient immune states.
Effectiveness and safety may vary with the patient’s immune state because these drugs can act through viral targets, host pathways, or innate antiviral defenses. Immunology and infection studies therefore need to consider how different immune conditions influence outcomes. This context helps determine whether an agent performs consistently across diverse patient populations.
Assessment should examine both effectiveness and safety across the viruses the drug is intended to address. Because broad activity depends on conserved viral steps or shared host dependencies, performance may not be uniform among pathogens. Testing across respiratory, systemic, and emerging viral diseases can clarify the agent’s practical range and limitations.
These drugs are particularly valuable when the causative virus is unknown or rapidly emerging, since treatment decisions may precede complete viral identification. Their wider potential coverage can support responses to diverse infections while more specific therapies are being selected or developed. This makes them relevant to outbreak preparedness as well as immediate infection research.
A broad-spectrum agent can provide activity across several viral possibilities, while a virus-specific drug focuses on a confirmed pathogen. Using these approaches as complementary options may support treatment of respiratory, systemic, or emerging diseases when diagnosis, viral evolution, or mixed clinical needs complicate therapy. Their combined role still requires careful effectiveness and safety evaluation.